Cargando…

Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network

AIMS: To explore the prevalence and describe the clinical characteristics of people with type 2 diabetes with a similar cardiovascular (CV) profile to that of the LEADER trial participants in a primary care setting in England. MATERIALS AND METHODS: In this cross‐sectional analysis, using the Royal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinton, William, Feher, Michael, Munro, Neil, Walker, Megan, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619442/
https://www.ncbi.nlm.nih.gov/pubmed/30900349
http://dx.doi.org/10.1111/dom.13710
_version_ 1783433930415800320
author Hinton, William
Feher, Michael
Munro, Neil
Walker, Megan
de Lusignan, Simon
author_facet Hinton, William
Feher, Michael
Munro, Neil
Walker, Megan
de Lusignan, Simon
author_sort Hinton, William
collection PubMed
description AIMS: To explore the prevalence and describe the clinical characteristics of people with type 2 diabetes with a similar cardiovascular (CV) profile to that of the LEADER trial participants in a primary care setting in England. MATERIALS AND METHODS: In this cross‐sectional analysis, using the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network database, we identified people with type 2 diabetes meeting the LEADER inclusion criteria. We identified people's CV risk factors using computerized medical records. Additionally, we assessed the prescription pattern of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in this cohort. RESULTS: Of 1 275 461 adults, we identified 84 394 with type 2 diabetes, of whom 14 000 (16.6%) met the LEADER inclusion criteria for established or high‐risk CV disease (RCGP RSC‐CVD group). The LEADER cohort was younger than the RCGP RSC‐CVD group (64.2 vs 73.2 years), had higher mean glycated haemoglobin (71.6 vs 67.1 mmol/mol) and blood pressure (BP) values (systolic BP: 135.9 vs 132.9 mmHg; diastolic BP: 77.2 vs 72.7 mmHg), and a higher mean body mass index (32.5 vs 30.9 kg/m(2)). In the RCGP RSC‐CVD group, only 1215 people (8.7%) had ever been prescribed a GLP‐1RA and 760 (5.4%) had ever received liraglutide. CONCLUSIONS: In a cohort of English general practice patients, one in six people with type 2 diabetes met the LEADER inclusion criteria, and less than one in 10 of these received liraglutide, a drug which has demonstrated CV benefits amongst others. There is scope to improve the outlook in people with type 2 diabetes and high CV risk through evidence‐based use of specific GLP‐1RAs.
format Online
Article
Text
id pubmed-6619442
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-66194422019-07-22 Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network Hinton, William Feher, Michael Munro, Neil Walker, Megan de Lusignan, Simon Diabetes Obes Metab Original Articles AIMS: To explore the prevalence and describe the clinical characteristics of people with type 2 diabetes with a similar cardiovascular (CV) profile to that of the LEADER trial participants in a primary care setting in England. MATERIALS AND METHODS: In this cross‐sectional analysis, using the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network database, we identified people with type 2 diabetes meeting the LEADER inclusion criteria. We identified people's CV risk factors using computerized medical records. Additionally, we assessed the prescription pattern of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in this cohort. RESULTS: Of 1 275 461 adults, we identified 84 394 with type 2 diabetes, of whom 14 000 (16.6%) met the LEADER inclusion criteria for established or high‐risk CV disease (RCGP RSC‐CVD group). The LEADER cohort was younger than the RCGP RSC‐CVD group (64.2 vs 73.2 years), had higher mean glycated haemoglobin (71.6 vs 67.1 mmol/mol) and blood pressure (BP) values (systolic BP: 135.9 vs 132.9 mmHg; diastolic BP: 77.2 vs 72.7 mmHg), and a higher mean body mass index (32.5 vs 30.9 kg/m(2)). In the RCGP RSC‐CVD group, only 1215 people (8.7%) had ever been prescribed a GLP‐1RA and 760 (5.4%) had ever received liraglutide. CONCLUSIONS: In a cohort of English general practice patients, one in six people with type 2 diabetes met the LEADER inclusion criteria, and less than one in 10 of these received liraglutide, a drug which has demonstrated CV benefits amongst others. There is scope to improve the outlook in people with type 2 diabetes and high CV risk through evidence‐based use of specific GLP‐1RAs. Blackwell Publishing Ltd 2019-04-11 2019-07 /pmc/articles/PMC6619442/ /pubmed/30900349 http://dx.doi.org/10.1111/dom.13710 Text en © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Hinton, William
Feher, Michael
Munro, Neil
Walker, Megan
de Lusignan, Simon
Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title_full Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title_fullStr Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title_full_unstemmed Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title_short Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
title_sort real‐world prevalence of the inclusion criteria for the leader trial: data from a national general practice network
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619442/
https://www.ncbi.nlm.nih.gov/pubmed/30900349
http://dx.doi.org/10.1111/dom.13710
work_keys_str_mv AT hintonwilliam realworldprevalenceoftheinclusioncriteriafortheleadertrialdatafromanationalgeneralpracticenetwork
AT fehermichael realworldprevalenceoftheinclusioncriteriafortheleadertrialdatafromanationalgeneralpracticenetwork
AT munroneil realworldprevalenceoftheinclusioncriteriafortheleadertrialdatafromanationalgeneralpracticenetwork
AT walkermegan realworldprevalenceoftheinclusioncriteriafortheleadertrialdatafromanationalgeneralpracticenetwork
AT delusignansimon realworldprevalenceoftheinclusioncriteriafortheleadertrialdatafromanationalgeneralpracticenetwork